|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CASP2 |
Gene summary for CASP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CASP2 | Gene ID | 835 |
| Gene name | caspase 2 | |
| Gene Alias | CASP-2 | |
| Cytomap | 7q34 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | D3DXD9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 835 | CASP2 | LZE4T | Human | Esophagus | ESCC | 6.86e-03 | 1.12e-01 | 0.0811 |
| 835 | CASP2 | LZE7T | Human | Esophagus | ESCC | 6.48e-04 | 4.12e-01 | 0.0667 |
| 835 | CASP2 | LZE20T | Human | Esophagus | ESCC | 5.25e-03 | 1.46e-01 | 0.0662 |
| 835 | CASP2 | LZE24T | Human | Esophagus | ESCC | 1.97e-08 | 1.93e-01 | 0.0596 |
| 835 | CASP2 | P1T-E | Human | Esophagus | ESCC | 6.87e-03 | 1.66e-01 | 0.0875 |
| 835 | CASP2 | P2T-E | Human | Esophagus | ESCC | 1.88e-04 | 1.23e-01 | 0.1177 |
| 835 | CASP2 | P4T-E | Human | Esophagus | ESCC | 8.69e-15 | 3.03e-01 | 0.1323 |
| 835 | CASP2 | P5T-E | Human | Esophagus | ESCC | 2.93e-15 | 2.69e-01 | 0.1327 |
| 835 | CASP2 | P8T-E | Human | Esophagus | ESCC | 2.20e-17 | 3.02e-01 | 0.0889 |
| 835 | CASP2 | P9T-E | Human | Esophagus | ESCC | 3.60e-02 | 1.44e-01 | 0.1131 |
| 835 | CASP2 | P10T-E | Human | Esophagus | ESCC | 1.23e-20 | 2.96e-01 | 0.116 |
| 835 | CASP2 | P12T-E | Human | Esophagus | ESCC | 5.79e-16 | 3.41e-01 | 0.1122 |
| 835 | CASP2 | P15T-E | Human | Esophagus | ESCC | 6.77e-21 | 4.34e-01 | 0.1149 |
| 835 | CASP2 | P16T-E | Human | Esophagus | ESCC | 1.30e-15 | 2.53e-01 | 0.1153 |
| 835 | CASP2 | P20T-E | Human | Esophagus | ESCC | 6.12e-03 | 9.55e-02 | 0.1124 |
| 835 | CASP2 | P21T-E | Human | Esophagus | ESCC | 6.48e-12 | 2.58e-01 | 0.1617 |
| 835 | CASP2 | P22T-E | Human | Esophagus | ESCC | 8.54e-10 | 1.63e-01 | 0.1236 |
| 835 | CASP2 | P23T-E | Human | Esophagus | ESCC | 2.02e-03 | 1.30e-01 | 0.108 |
| 835 | CASP2 | P24T-E | Human | Esophagus | ESCC | 2.03e-09 | 1.57e-01 | 0.1287 |
| 835 | CASP2 | P26T-E | Human | Esophagus | ESCC | 2.06e-08 | 1.82e-01 | 0.1276 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:009719320 | Oral cavity | OSCC | intrinsic apoptotic signaling pathway | 202/7305 | 288/18723 | 4.64e-27 | 1.73e-24 | 202 |
| GO:004586220 | Oral cavity | OSCC | positive regulation of proteolysis | 236/7305 | 372/18723 | 6.53e-22 | 1.38e-19 | 236 |
| GO:00447728 | Oral cavity | OSCC | mitotic cell cycle phase transition | 255/7305 | 424/18723 | 5.29e-19 | 6.98e-17 | 255 |
| GO:00073469 | Oral cavity | OSCC | regulation of mitotic cell cycle | 266/7305 | 457/18723 | 3.87e-17 | 3.41e-15 | 266 |
| GO:200011620 | Oral cavity | OSCC | regulation of cysteine-type endopeptidase activity | 152/7305 | 235/18723 | 1.14e-15 | 8.13e-14 | 152 |
| GO:004328120 | Oral cavity | OSCC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 137/7305 | 209/18723 | 5.94e-15 | 3.80e-13 | 137 |
| GO:009719120 | Oral cavity | OSCC | extrinsic apoptotic signaling pathway | 142/7305 | 219/18723 | 7.34e-15 | 4.55e-13 | 142 |
| GO:200123510 | Oral cavity | OSCC | positive regulation of apoptotic signaling pathway | 92/7305 | 126/18723 | 8.45e-15 | 5.19e-13 | 92 |
| GO:005254720 | Oral cavity | OSCC | regulation of peptidase activity | 255/7305 | 461/18723 | 5.78e-13 | 2.75e-11 | 255 |
| GO:007149620 | Oral cavity | OSCC | cellular response to external stimulus | 186/7305 | 320/18723 | 2.56e-12 | 1.05e-10 | 186 |
| GO:007233120 | Oral cavity | OSCC | signal transduction by p53 class mediator | 107/7305 | 163/18723 | 4.75e-12 | 1.83e-10 | 107 |
| GO:000756818 | Oral cavity | OSCC | aging | 194/7305 | 339/18723 | 6.18e-12 | 2.33e-10 | 194 |
| GO:000863018 | Oral cavity | OSCC | intrinsic apoptotic signaling pathway in response to DNA damage | 72/7305 | 99/18723 | 9.50e-12 | 3.50e-10 | 72 |
| GO:001095220 | Oral cavity | OSCC | positive regulation of peptidase activity | 123/7305 | 197/18723 | 2.12e-11 | 7.21e-10 | 123 |
| GO:19019905 | Oral cavity | OSCC | regulation of mitotic cell cycle phase transition | 173/7305 | 299/18723 | 2.49e-11 | 8.35e-10 | 173 |
| GO:007099720 | Oral cavity | OSCC | neuron death | 202/7305 | 361/18723 | 3.75e-11 | 1.23e-09 | 202 |
| GO:005160410 | Oral cavity | OSCC | protein maturation | 170/7305 | 294/18723 | 3.97e-11 | 1.28e-09 | 170 |
| GO:005254820 | Oral cavity | OSCC | regulation of endopeptidase activity | 235/7305 | 432/18723 | 4.35e-11 | 1.40e-09 | 235 |
| GO:007121416 | Oral cavity | OSCC | cellular response to abiotic stimulus | 186/7305 | 331/18723 | 1.38e-10 | 4.10e-09 | 186 |
| GO:010400416 | Oral cavity | OSCC | cellular response to environmental stimulus | 186/7305 | 331/18723 | 1.38e-10 | 4.10e-09 | 186 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0421027 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
| hsa0421037 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
| hsa0421018 | Oral cavity | OSCC | Apoptosis | 101/3704 | 136/8465 | 3.34e-13 | 7.00e-12 | 3.56e-12 | 101 |
| hsa0421019 | Oral cavity | OSCC | Apoptosis | 101/3704 | 136/8465 | 3.34e-13 | 7.00e-12 | 3.56e-12 | 101 |
| hsa0421026 | Oral cavity | LP | Apoptosis | 65/2418 | 136/8465 | 1.33e-06 | 1.48e-05 | 9.53e-06 | 65 |
| hsa0421036 | Oral cavity | LP | Apoptosis | 65/2418 | 136/8465 | 1.33e-06 | 1.48e-05 | 9.53e-06 | 65 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CASP2 | SNV | Missense_Mutation | c.23N>T | p.Ser8Phe | p.S8F | P42575 | protein_coding | tolerated_low_confidence(0.1) | benign(0) | TCGA-A2-A04Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| CASP2 | SNV | Missense_Mutation | novel | c.905N>G | p.Asn302Ser | p.N302S | P42575 | protein_coding | tolerated(0.07) | probably_damaging(0.998) | TCGA-A2-A4RY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | CR |
| CASP2 | insertion | In_Frame_Ins | novel | c.553_554insAAACACACTTCCAGCTGGTGAGTTTTTGCATAA | p.Leu190_Ala191insValSerPheCysIleLysThrHisPheGlnLeu | p.L190_A191insVSFCIKTHFQL | P42575 | protein_coding | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
| CASP2 | SNV | Missense_Mutation | c.249N>C | p.Gln83His | p.Q83H | P42575 | protein_coding | deleterious(0.01) | probably_damaging(0.985) | TCGA-IR-A3LF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CASP2 | SNV | Missense_Mutation | rs139233385 | c.794N>A | p.Arg265Gln | p.R265Q | P42575 | protein_coding | tolerated(0.28) | benign(0.011) | TCGA-VS-A9U5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CASP2 | insertion | Frame_Shift_Ins | novel | c.3_4insGCGGC | p.Pro4ArgfsTer16 | p.P4Rfs*16 | P42575 | protein_coding | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | ||
| CASP2 | SNV | Missense_Mutation | rs756201685 | c.907N>A | p.Ala303Thr | p.A303T | P42575 | protein_coding | deleterious(0.01) | probably_damaging(0.978) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| CASP2 | SNV | Missense_Mutation | rs144817015 | c.464N>A | p.Arg155His | p.R155H | P42575 | protein_coding | tolerated(0.22) | benign(0.01) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| CASP2 | SNV | Missense_Mutation | rs141615673 | c.718G>A | p.Val240Ile | p.V240I | P42575 | protein_coding | deleterious(0.05) | benign(0.029) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CASP2 | SNV | Missense_Mutation | rs370097426 | c.814N>A | p.Val272Met | p.V272M | P42575 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AZ-6599-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 835 | CASP2 | PROTEASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL197672 | EMRICASAN | |
| 835 | CASP2 | PROTEASE, DRUGGABLE GENOME, ENZYME | inhibitor | 252166828 | ||
| 835 | CASP2 | PROTEASE, DRUGGABLE GENOME, ENZYME | CETYLPYRIDINIUM CHLORIDE | CETYLPYRIDINIUM CHLORIDE | 18366176 | |
| 835 | CASP2 | PROTEASE, DRUGGABLE GENOME, ENZYME | SPERMINE | SPERMINE | 18366176 | |
| 835 | CASP2 | PROTEASE, DRUGGABLE GENOME, ENZYME | inhibitor | 178101981 | ||
| 835 | CASP2 | PROTEASE, DRUGGABLE GENOME, ENZYME | N-DECYLBUTYRAMIDE | CHEMBL265439 | 18366176 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |